| Swedish pharmaceutical research to accelerate |
|
|
|
Strengthen clinical research, invest in national coordination and focus on the four main diseases. How can the international pharmaceutical industry are attracted to Sweden again, does academia, industry and government.
Sweden's largest export industry is paper and cardboard. As a close
second, the life science, an area where companies in biotechnology,
pharmaceuticals and medical matters. Exports amounted to 210 billion
dollars a year and has 50 000 employees.
But the industry is undergoing a tough restructuring. For Sweden, it became apparent after Astra Zeneca spent research in Lund and most recently in Sodertalje. Growth in the pharmaceutical industry is hardly significant, said Richard Bergstrom, director of the European pharmaceutical industry association. The exception is vaccination where there has been considerable growth in recent years. The question is how research on pharmaceuticals in Sweden should be strengthened were discussed during a seminar, organized by the Chamber of Commerce. According to Richard Bergstrom is the attitude towards Europe among the world's 25 largest pharmaceutical companies - BigPharma-not as positive. They invest where they feel welcome, and where the attitude to new drugs is positive. It does not feel that it is in Europe. The result is that Europe, and Sweden, lost in clinical research. But there are other factors that play a role. Now it's drugs that are adapted to the individual patient and the so-called human medicine. Because even if two patients have the same diagnosis is not certain that the medicine helps both. Around 3/4 of the drugs found in the spout of the big pharmaceutical companies are of this type, says Richard Bergstrom. Then you have to have such a large patient base that you can pick up 100 people with the right profile and that may be included in a clinical study. Harriet Wallberg - Henriksson, president of the Karolinska Institute, said that one must get to a scale. Therefore, four diagnoses are prioritized; breast cancer, type 2 diabetes, rheumatic diseases, and heart / vascular diseases such as heart failure and / or thrombosis. Harriet Wallberg - Henriksson looks Research Centre SciLifeLab as an important part of the solution how to get to that in Sweden. Here are the ability to handle large amounts of clinical material. But we need a national funnel for drug trials, she says. The idea is not foreign to Peter Honeth, State Secretary at the Ministry of Education: We are strong in terms of basic research. But research has to be good all the way to clinical research. I think it is necessary to have a national function for it. But we must also ensure that you have a good tax system, said Peter Honeth. |
| < Prev | Next > |
|---|
